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The Crystal Structure of Human Angiogenin
in Complex with an Antitumor Neutralizing Antibody
have been determined. Although the fold of the protein
is similar to those of pancreatic RNase A and other
homologs, ANG contains unique structural features that
Gayatri B. Chavali,1,5,6
Anastassios C. Papageorgiou,1,5,7
Karen A. Olson,2 James W. Fett,2 Guo-fu Hu,2,4
Robert Shapiro,2,3 and K. Ravi Acharya1,* account for its characteristic enzymatic and angiogenic
activities.1Department of Biology and Biochemistry
University of Bath ANG is produced by many distinct types of human
tumor cells grown in culture (Fett et al., 1985; Rybak etClaverton Down
Bath BA2 7AY al., 1987; Adams and Subramanian, 1999), and, in sev-
eral studies, its expression has been positively corre-United Kingdom
2 Center for Biochemical and Biophysical Sciences lated with cancer progression and poor prognosis (e.g.,
Li et al., 1994; Shimoyama et al., 1996; Eberle et al.,and Medicine
3 Department of Pathology 2000). It has therefore been of interest to identify inhibi-
tors of the functions of ANG and to evaluate their poten-4 Department of Radiology
Harvard Medical School tial utility in the treatment and/or prevention of cancer.
One of the earliest antagonists was the murine mono-One Kendall Square
Cambridge, Massachusetts 02139 clonal antibody (mAb) 26-2F. It is an IgG1, with an IC50
binding affinity of 1.6 nM, that neutralizes the ribonucleo-
lytic, angiogenic, and mitogenic activities of human ANG
(Fett et al., 1994; Hu et al., 1997).Summary
Preclinical studies have shown that mAb 26-2F is re-
markably effective in preventing the establishment ofThe murine monoclonal antibody 26-2F neutralizes the
primary (Olson et al., 1994, 1995) and metastatic humanangiogenic and ribonucleolytic activities of human an-
tumors (Olson et al., 2002) of various histological typesgiogenin (ANG) and is highly effective in preventing the
in athymic mice. Thus, immunotherapeutic neutraliza-establishment and metastatic dissemination of human
tion of ANG might be a powerful broad-spectrum anti-tumors in athymic mice. Here we report a 2.0 A˚ resolu-
cancer approach. However, repeated use of murine anti-tion crystal structure for the complex of ANG with
bodies for the treatment of human disease can elicitthe Fab fragment of 26-2F that reveals the detailed
undesirable antimouse immune responses (Levy andinteractions between ANG and the complementarity-
Miller, 1983; Lobuglio et al., 1986). In order to minimizedetermining regions (CDRs) of the antibody. Surpris-
these side effects, we initially constructed a chimericingly, Fab binding induces a dramatic conformational
version of mAb 26-2F, in which the murine constant (C)change in the cell binding region of ANG at the oppo-
region segments have been replaced through geneticsite end of the molecule from the combining site; cross-
engineering with human immunoglobulin sequenceslinking experiments indicate that this rearrangement
(Piccoli et al., 1998). In a mouse model for breast canceralso occurs in solution. The ANG-Fab complex structure
establishment, the antitumor activity of this antibodyshould be invaluable for designing maximally human-
is identical to that of its murine counterpart. Althoughized versions of 26-2F for potential clinical use.
chimeric antibodies have reduced immunogenicity, pa-
tients treated with them have developed untoward im-Introduction
mune responses that are directed against the remaining
mouse variable (V) region residues (Choy et al., 1993,Angiogenin (ANG) is a secreted, single-chain 14,143 Da
1994). As a result, humanized versions of murine mAbsprotein that induces angiogenesis in vivo (Riordan, 1997;
are emerging as preferred therapeutics. In contrast toAdams and Subramanian, 1999). It was isolated origi-
chimerized IgG antibodies, which still contain 33%nally from medium conditioned by human colon carci-
mouse sequences, humanized IgG counterparts maynoma cells (Fett et al., 1985) and subsequently from
contain less than 5% of unwanted murine residues. Sev-normal serum and milk (Shapiro et al., 1987; Maes et al.,
eral of these derivatives have now entered clinical trials1988). ANG is a member of the pancreatic RNase super-
(Carter, 2001).family and possesses a ribonucleolytic activity (Shapiro
A typical strategy used to construct humanized anti-et al., 1986) that is necessary for its blood vessel-inducing
bodies is to graft murine complementarity-determiningcapability (Shapiro et al., 1989; Shapiro and Vallee 1989).
regions (CDRs) into consensus human framework re-The three-dimensional structures of human (Acharya et
gions (Presta et al., 1997). However, this process oftenal., 1994; Lequin et al., 1997; Leonidas et al., 1999) and
results in antibody products exhibiting less than optimalbovine ANG (Acharya et al., 1995; Lequin et al., 1996)
binding characteristics (Queen et al., 1989; Foote and
Winter, 1992). A procedure of trial and error is then
*Correspondence: k.r.acharya@bath.ac.uk required, in which CDR regions are manipulated and
5These authors contributed equally to this work. selected murine-derived framework residues are incor-6Present address: Cambridge Institute of Medical Research, MRC/
porated to maintain or enhance the binding affinity ofWellcome Trust Building, Cambridge CB2 2XY, United Kingdom.
the parent antibody (Riechmann et al., 1988). As an alter-7Present Address: Turku Centre for Biotechnology, University of
Turku and A˚bo Akademi University, BioCity, Turku 20521, Finland. native, we have opted to pursue our goal of engineering
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a  b  c (A˚) 120.6  72.5  87
 () 112.5
Resolution range 40–2.0 A˚
Number of unique reflections 46,470
Average I/(I) 17.6 (4.92)a
Overall completeness (%) 98.9 (97.8)a






Total number of residues 562
Contents of asymmetric unit 1 Fab-ANG complex
Total number of protein atoms 4280
Total number of water molecules 328
Ions/ligands 8 sulfates and 6 glycerols
Average B factor (A˚2) 39.7
Average B Factors (A˚2) for Residues
Light Chain Heavy Chain ANG
Overall 37.6 41.4 37.1
Main chain 36.8 41.5 35.9
Side chain 38.5 41.3 38.2
Water molecules (average) 42.7
Stereochemistry (Rmsd from Ideality)
Bond lengths (A˚) 0.009
Bond angles () 1.8
Dihedrals () 26.8
Improper angles () 1.3
a Outermost shell  2.07–2.00 A˚.
b Rmerge  hi|I(h )  Ii(h )|/hiIi(h ), where I(h ) and Ii(h ) are the mean and ith measurements of the intensity of reflection h, respectively.
c Rcryst  h|Fo  Fc|/hFo, where Fo and Fc are the observed and calculated structure factor amplitudes of reflection h, respectively.
d Rfree is equal to Rcryst for a randomly selected 5 % subset of reflections not used in the refinement.
humanized versions of mAb 26-2F by first determining 1:1 complex and is shown in Figure 1. Residues 128–133
the three-dimensional structure of the complex of the in the C region of the Fab heavy (H) chain (Figure 2) could
26-2F Fab fragment with ANG. This structure reveals the not be positioned unambiguously and were modeled as
details of the binding epitope and identifies framework glycines. These residues are reported to be highly mo-
residues that support the conformational integrity of the bile in other antibody structures (Schneider et al., 1988;
CDRs. Moreover, it indicates that neutralization of ANG Sheriff et al., 1996). No density was observed for the
function by the antibody is achieved through an unusual side chain atoms of light (L) chain C region residues
mechanism involving both direct interactions with the 198–199 and 210–211, H chain C region residues 134 and
active site region and the induction of an extensive reor- 213–215, and the N-terminal pyroglutamic acid (	Glu) of
ganization of the cell binding site at the opposite end ANG; these were modeled as alanines. The refined
of the ANG molecule. These findings should greatly facil- model includes 562 protein residues, 328 water mole-
itate the design of high-affinity humanized mAb 26-2F cules, 8 sulfate ions, and 6 glycerol molecules. Analysis
counterparts for use in the treatment of human cancers with PROCHECK (Laskowski et al., 1993) indicated that
and other ANG-dependent diseases. the φ-
 conformational angles were within the limits
expected for a structure at this resolution, with only one
residue (L198) in the disallowed region of the Ramachan-Results and Discussion
dran plot (87.4% in the core). The electron density map
indicated that there were three variations in the C re-The structure of the ANG-Fab complex was determined
gions with respect to the published consensus aminoat 2.0 A˚ resolution and refined to a crystallographic R
acid sequence for this antibody subclass (Kabat et al.,factor of 23.2% (Rfree  27.2%). Details of the data pro-
1991); residues 146 and 165 in the CL region were identi-cessing and refinement statistics are given in Table 1.
The crystallographic asymmetric unit contains a single fied as Arg and Gln, instead of Lys and Glu, respectively,
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of 1.27 A˚ and 0.79 A˚, respectively. The elbow angles are
132.3 for 26-2F and 173.8 for D44.1; both are within
the broad range of 125–225 normally observed for Fab
fragments (Wilson and Stanfield, 1994).
The six CDR loops of Fab 26-2F (L1, L2, and L3 from
VL and H1, H2, and H3 from VH) are well defined in the
electron density map. Although CDR sequences vary
considerably from one antibody to another, most CDRs
adopt one of a set of canonical structures. In Fab 26-
2F, CDRs L1, L2, L3, H1, and H2 can be assigned to
canonical classes 5, 1, 1, 1, and 3, respectively, de-
scribed by Chothia and coworkers (Chothia and Lesk,
1987; Chothia et al., 1989; Al-Lazikani et al., 1997). CDR-
H3 in antibodies is far more variable than the others in
length, sequence, and conformation, and no canonical
structures have been described for it, although certain
regularities have been observed. Mas et al. (1992) have
noted two types of backbone conformations at the base
of the loop, kinked and extended, reflecting the pres-
ence and absence, respectively, of a bulge around the
second residue from the C-terminal end. The 12-residue
H3 loop of Fab 26-2F (H95–H102) has the more common
kinked structure and forms both of the interactions usu-
ally associated with this conformation, i.e., a salt bridge
between an Asp (H101) two residues from the C-terminal
end and a framework Arg (H94) that immediately pre-
cedes the loop and a hydrogen bond between the car-
bonyl oxygen of the same Asp and the N1 atom of the
highly conserved framework Trp (H103) that immediately
follows the loop (Shirai et al., 1996; Morea et al., 1998).
Three of the four tyrosines in CDR-H3 are involved in
hydrophobic packing or stacking interactions with the
light chain. H98 (Tyr) and H100b (Tyr) contact L32 (Phe)
of CDR-L1, and H98 also interacts with L30b (Tyr) and
L30d (Ile) of CDR-L1. H100 (Tyr) stacks against L49 (Tyr),
the first framework residue on the N-terminal side of
L2. Interactions with framework residues also appear to
stabilize the conformation of CDR-H2; the side chain
OH of H50 (Thr) hydrogen bonds with the N1 atom of
Figure 1. Structure of the Complex Formed between Human ANG H47 (Trp), and the main chain O of H52 (Ser) hydrogen
and Fab 26-2F
bonds with N1 of H71 (Arg).
The L and H chains of the Fab molecule are in magenta and blue,
The structure of 	Glu-1 ANG in the complex is similarrespectively, except for their CDRs (L1–L3 and H1–H3), which are
to that of free ANG (Protein Data Bank code 1B1I; Leoni-in gold and cyan, respectively. ANG, green. Sulfate ions (yellow
das et al., 1999), except for the cell binding region (de-bonds) and glycerol molecules (green bonds) are also shown. The
figure was generated with MOLSCRIPT (Kraulis, 1991). tailed below). Superposition of 108 C atoms in the free
and complexed proteins (i.e., excluding the three N-ter-
minal and two C-terminal residues, as well as amino
and residue 189 in the CH region was found to be Trp, acids 59–68 in the cell binding site) resulted in an rmsd
instead of Arg. These residues are not located at the of 0.86 A˚.
contact interface. Nine cis-prolines were identified in
the structure, seven of which are in the Fab. Most of
these appear to be conserved in the majority of mouse The Antigen-Antibody Interface
Fab 26-2F recognizes two discontinuous segments ofIgG1 sequences (Sheriff et al., 1996).
ANG comprising residues 34–41 (segment I) and 85–91
(segment II); these segments lie on two surface loopsOverall Structure of the Complex
The conformation of Fab 26-2F closely resembles that that are juxtaposed in the three-dimensional structure
(Figures 1 and 4) and are linked by the Cys39-Cys92of the Fab for murine monoclonal antibody D44.1 (also
an IgG1) raised against hen egg white lysozyme (Pro- disulfide bridge. Five of the six CDRs of the Fab (i.e.,
all but L2) make contacts with ANG. Formation of thetein Data Bank code 1MLB) (Braden et al., 1994). The
two structures can be superposed with an rmsd of 1.64 A˚ complex buries 1326 A˚2 of the solvent-accessible sur-
face area of the proteins: 649 A˚2 for the antibody (38%(421 C atoms) (Figure 3). This value decreases only to
1.56 A˚ when the CDR regions are omitted. The separate from the L chain and 62% from the H chain) and 677 A˚2
for ANG (43% from segment I and 57% from segmentV and C domains correspond more closely, with rmsd’s
Structure
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Figure 2. Amino Acid Sequences of Fab 26-
2F and Human ANG
The antibody V region sequences are those
deduced from the DNA sequence (Piccoli et
al., 1998); GenBank accession numbers are
AF039414 (VL) and AF039415 (VH). Residue
numbering is that of Chothia and Lesk (1987).
Residues that are highly conserved in this IgG
subclass are shown in bold italic type. The
six CDR loops as defined by the antibody
modeling programs AbM (Oxford Molecular)
and WAM (Whitelegg and Rees, 2000; https://
antibody.bath.ac.uk/WAMpredict.html) are
underlined; these definitions differ from those
of Chothia and coworkers (Chothia and Lesk,
1987; Chothia et al. 1989; Al-Lazikani et al.,
1997) only for CDRs H1 and H2. The DNA
sequences for the CL and CH regions have not
been determined; the amino acid sequences
shown are those from MOPC 41 and MOPC
21, respectively (Kabat et al., 1991), except
for three residues (L146, L165, and H89)
where the crystal structure clearly reveals dif-
ferences. The ANG sequence is from Strydom
et al. (1985). Residues involved in intermolec-
ular contacts are highlighted in magenta.
II). The total value is toward the lower end of the range The shallow binding pocket on the surface of the anti-
body is formed by CDRs L1 and H3 on one side and L3,reported for other complexes of Fab fragments with
protein antigens (Davies and Cohen, 1996; Jones and H2, and H1 on the other. Segments I and II of ANG fit
snugly into this pocket (Figure 4); both segments haveThornton, 1996). In all, 14 residues from ANG and 17
from the Fab participate in the interface, forming 81 van moved slightly from their positions in free ANG to opti-
mize contacts with the Fab. The most extensively in-der Waals contacts (Table 2) and 13 potential hydrogen
bonds (Table 3). volved CDR is H2, which forms interactions with every
Figure 3. Stereo View of the Superposed C
Backbones of the Fab Molecule from the
ANG-Fab 26-2F Complex (Magenta) and Fab
D44.1 (Protein Data Bank Code 1MLB; Blue)
The locations of the CDRs (L1–L3 and H1–H3)
are indicated.
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at the interface appears to be H1, which makes only aTable 2. Van der Waals Contacts between Fab and ANG in the
Complex single interaction with ANG.
As observed in other antigen-antibody complexesFab CDR Fab Residue ANG Residue Number of Contacts
(Padlan, 1990; Davies and Cohen, 1996; Sogabe et al.,
L1 Asn30a Ser37 3 1997), aromatic residues seem to play a major role in the
Tyr30b Gly34 1
binding of ANG to the Fab. The five aromatic interfaceLeu35 7
residues on the Fab account for 66% of the total con-Ser37 1
tacts, and Trp89 of ANG alone is involved in 23% of thePro38 4
Lys40 3 interactions. Indeed, the most dominant feature of the
Phe32 Pro38 8 interface is the complete burial of Trp89 in the antibody
L3 Lys92 Ser37 2 (the accessible surface area of this residue decreases
Pro38 1
from 181 A˚2 in free ANG to 0 A˚2 in the complex).Glu93 Trp89 1
The interface contains 11 buried water molecules, noneVal94 Trp89 3
of which are involved in water-mediated hydrogen bondsLeu96 Trp89 5
H2 Thr50 Trp89 1 between ANG and the Fab. However, two water mole-
Ser52 Gly85 1 cules participate in a hydrogen-bonding network that
Gly86 1 extends from Gly86 O of ANG to H98 (Tyr) N and H102b
Ser52a Gly85 1
(Tyr) OH of the Fab. The sulfate ions identified in the struc-Gly86 1
ture are not at the binding interface, although two interactGly53 Gly85 1
with residues that also form intermolecular contacts (Lys40Asn56 Ser87 1
Pro91 2 of ANG and residue 52a [Ser] on CDR-H2).
Tyr58 Ser87 1
Pro88 2 Correlation of Structural Data with Results from
Trp89 9
Epitope-Mapping Studies on mAb 26-2FPro90 1
mAb 26-2F was shown previously to inhibit the ribo-H3 Tyr98 Cys39 1
nucleolytic activity of ANG (Fett et al., 1994), suggestingLys40 2
Asp41 8 that it contacts the enzymatic active site. The crystal
Tyr100b Pro38 4 structure of the Fab complex reveals that the antibody
Cys39 1 indeed interacts with a key catalytic residue, Lys40, on
Pro88 4
segment I. Although the contacts formed involve only
The program CONTACT (CCP4, 1994) was used for calculations the alkyl chain of this residue, rather than the N atom
(distance cutoffs: C-C, 4.1 A˚; C-N, 3.8 A˚; C-O, 3.7 A˚; N-N, 3.4 A˚; that participates in catalysis (Leonidas et al., 1999), bind-
O-O, 3.3 A˚; and O-N, 3.4 A˚).
ing of the antibody at this position should be sufficient
to block access to the active site by RNA substrates.
Experiments to map the binding epitope on ANG in
greater detail were performed with an extensive panelresidue on segment II of ANG, including five hydrogen
bonds with the main chain of this segment (Tables 2 of ANG variants and several nonhuman angiogenins
(Fett et al., 1994). The results of this study are in com-and 3). CDR-L1 plays a similarly pivotal role vis-a`-vis
segment I of ANG, interacting with five of the seven plete agreement with the crystal structure. A 300-fold
increase in apparent Kd for the complex was observedcontact residues and making three hydrogen bonds,
again with main chain elements. (Indeed, it is striking with an ANG variant (ARH-II) in which residues 38–41
(Pro-Cys-Lys-Asp) are replaced by the correspondingthat all but two of the hydrogen bonds of the Fab are
with the main chain of ANG.) CDRs L3 and H3 contact residues of RNase A (Asp-Arg-Cys-Lys-Pro), suggesting
that the 38–41 segment of ANG contains an importantboth segments on ANG. The least utilized of the CDRs
Table 3. Potential Hydrogen Bonds between Fab 26-2F and ANG in the Complex Structure
Fab CDR Fab Residue ANG Residue Distance (A˚) Angle ()
L1 Asn30a N2 (33.8) Ser37 O (31.9) 2.7 135
Tyr30b OH (32.2) Ser37 N (28.2) 3.0 115
Pro38 O (26.1) 2.6 154
L3 Ser91 O (29.9) Trp89 N1 (28.4) 3.0 174
Lys92 N (31.1) Ser37 O (35.3) 2.5 126
Ser37 O (31.9) 3.2 122
H1 Thr33 O1 (37.1) Gly86 O (31.9) 3.3 131
H2 Ser52a O (42.1) Gly85 O (34.0) 3.1 95
Gly53 N (45.9) Gly85 O (34.0) 2.9 132
Asn56 O1 (47.6) Pro91 O (30.8) 3.3 141
Tyr58 OH (32.5) Trp89 O (26.1) 2.9 129
Trp89 N (27.4) 3.4 162
H3 Tyr100b OH (23.5) Cys39 O (27.2) 2.8 152
Hydrogen bond parameters were calculated with the program CONTACT (CCP4, 1994). The donor-acceptor cutoff distance is 3.4 A˚, and
donor-hydrogen-acceptor angles are 90. The B factors (A˚2) of the atoms are given in parentheses.
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Figure 4. Structural Details of the Interac-
tions at the ANG/Fab 26-2F Interface
(A) The interface region of the complex of Fab
26-2F and ANG, showing the van der Waals
surface for the Fab, stick representations (in
standard colors) for ANG residues that con-
tact the antibody, and a trace for the ANG
backbone (magenta). The CDRs of the Fab,
green. The figure was generated with the pro-
gram DINO (A. Philippsen; http://cobra.mih.
unibas.ch/dino/).
(B) Stereo view of the details of the hydrogen
bonding contacts in the complex. Hydrogen
bonding residues on ANG and the Fab are
shown as stick representations, along with
their respective backbone traces (magenta
and green, respectively). CDRs are labeled
in bold type. Potential hydrogen bonds are
drawn as broken lines.
part of the binding epitope. These amino acids lie on Structural Changes in the Cell Binding Region
of ANG Due to Fab 26-2F Bindingsegment I of the epitope identified in the crystal struc-
ture. The substitution should alter its three-dimensional Remarkably, a segment of ANG (59–68) at the opposite
end of the molecule from the Fab combining site adoptsstructure (including the main chain) considerably and
would therefore eliminate most of the interactions a dramatically different conformation in the Fab complex
as compared to the free protein (Figure 5) and occupiesformed by this segment with the antibody. The major
role for Trp89 inferred from the crystal structure is sup- almost entirely nonoverlapping spaces in the super-
posed structures (the rmsd for C atoms is 13.2 A˚). Inported by the absence of any detectable binding for
mouse ANG, in which this Trp is replaced by Arg and free ANG, residues 62–68 are part of a  hairpin formed
by  strands 2 and 3 (residues 62–65 and 69–72, respec-all other residues on segments I and II are conserved.
An 3-fold loss in affinity was measured when Trp89 tively) and the intervening 66–68 loop; residues 59–61
lie on a loop that connects the hairpin structure with was substituted by a methionine, which can partially
fulfill the same function as the Trp in the complex. A helix 3. In the complex, the 2 strand is lost, and the
entire 58–67 segment forms a loop that extends muchminor decrease in affinity was seen for the K40Q variant,
consistent with the relatively small role for Lys40 sug- farther out from the rest of the ANG molecule than does
the  hairpin. The structure of this loop appears to begested by the crystal structure. Substitutions that in-
volve 26 additional ANG residues outside the structurally maintained by nine intraloop hydrogen bonds and two
hydrogen bonds with outside residues (Arg5 and Arg70).defined binding epitope had no significant impact on
antibody binding. The 60–68 segment of ANG has been demonstrated
Angiogenin-Fab 26-2F Complex Structure
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piro and Vallee, 1992) all abolish angiogenic activity
without influencing ribonucleolytic activity appreciably,
and most of the angiogenically inactive derivatives have
been shown to lack the capacity to inhibit ANG-induced
angiogenesis (in contrast with angiogenically inactive
catalytic site variants). On the basis of these findings,
the region containing the 60–68 segment was proposed
to constitute a cell binding site. The endothelial cell
targets of ANG display at least two molecules on their
surface (an ANG receptor and an ANG binding protein
[ANGBP] in the actin family) that participate in the angio-
genic mechanism (Hu and Riordan, 1993; Hu et al., 1993,
1997), and modifications within the 60–68 segment im-
pede the interactions with both of them (Hu et al., 1991;
G.-f.H. and R.S., unpublished data). This region most
likely does not retain any significant affinity for cellular
targets when it adopts the conformation seen in the
Fab complex. It is therefore of considerable interest to
ascertain whether this restructuring is triggered by the
binding of the antibody or whether it is a consequence
of packing in the crystal.
To the best of our knowledge, there is no precedent
for crystallization causing such a drastic structural reor-
ganization, involving the destruction of a well-ordered
region of the secondary structure (as opposed to the
reshaping of a flexible loop). Clearly, the conformation
of the 59–68 segment in the free ANG crystal structure
is not determined by crystal packing; the NMR solution
structure (all 30 sets of coordinates; Lequin et al., 1997)
shows a high degree of similarity in this region, as do
the crystal structures of wild-type bovine ANG and all
seven human ANG variants examined to date (Acharya
et al., 1994, 1995; Leonidas et al., 1999, 2002). Moreover,
it seems unlikely that the conformation of this segment
in the Fab complex is dictated by crystal contacts; al-
though ANG residues 62, 64, and 65 pack against CL of
the Fab in a symmetry-related molecule, only a single
hydrogen bond is formed, and the other interactions (all
van der Waals, with little burying of hydrophobic groups)
are not expected to provide much energy for stabiliza-
tion. However, inspection of the free ANG and ANG-Fab
structures does not reveal any obvious mechanism by
which attachment of the Fab to segments I and II would
induce the restructuring of the cell binding region more
than 20 A˚ away.
Direct evidence that binding of mAb 26-2F induces
the observed conformational change was obtained by
examining the effect of the antibody on the interaction
of ANG with ANGBP in solution (Figure 6). 125I-ANG can
Figure 5. Superposition of the C Atoms of Free ANG (Protein Data be readily crosslinked to endothelial cell ANGBP, pro-
Bank Code 1B1I; Orange) and ANG from the Fab 26-2F Complex ducing a band with an apparent Mr of 58,000 during(Dark Green)
SDS-PAGE (Hu et al., 1991) (lane 2). The intensity of
The two loops that contact the Fab are indicated. The region con-
this band is reduced by 65%  5% (results of threetaining cell binding site residues 60–68 is circled and shown below
independent experiments) if the labeled ANG is preincu-with a portion of the Fo  Fc electron density map clearly showing
bated with a 10-fold molar excess of mAb 26-2F prior tothe deviation in the conformation of this region in Fab-bound ANG.
The map is contoured at 3.0 . The figure was created with BOBS- addition of the binding protein and crosslinking reagent
CRIPT (Esnouf, 1997) and RASTER 3D (Merritt and Bacon, 1997). (lane 4). This effect does not reflect crosslinking of ANG
to the mAb because only a small amount of crosslinked
ANG-mAb complex is observed when the ANG binding
previously to play a critical functional role that is inde- protein is omitted (lane 3), and there is no band at the
pendent of catalysis. Cleavage of the 60/61 or 67/68 expected position of the ternary complex when all three
peptide bond (Hallahan et al., 1991), deamidation of Asn61 components are included (lane 4). Moreover, preincuba-
tion with two other mAbs (36u and 32-B5) has no effect(Hallahan et al., 1992), and Ala substitution of Arg66 (Sha-
Structure
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tact ANG. This approach has been used previously for
other antibodies (see Berezov et al., 2001, and refer-
ences therein).
A completely unexpected feature of the ANG-Fab 26-
2F structure was the marked perturbation of the cell
binding site of ANG induced by attachment of the anti-
body. Earlier work on mAb 26-2F had correctly identified
the region of ANG containing residues 38–41 and 89
(i.e., the region most distant from the cell binding site)
as the binding epitope, and had indicated that neutral-
ization of the angiogenic activity was due to inhibition
Figure 6. Effect of mAb 26-2F on the Binding of ANG to ANG Binding
of the ribonucleolytic activity of ANG. It now appearsProtein (ANGBP)
that the antibody disables ANG via a second, indirect125I-ANG was incubated for 30 min in the presence or absence of a
route as well, i.e., by destroying the native conformation10-fold molar excess of mAb prior to addition of ANGBP or PBS.
of a segment that is critical for the interactions of ANGAfter 10 min of further incubation, samples were subjected to cross-
linking with carbodiimide and then analyzed by SDS-PAGE and with surface components on its endothelial cell targets.
autoradiography. Lane 1, ANG alone; lane 2, ANG plus ANGBP;
lanes 3, 5, and 7, ANG plus mAb 26-2F, 36u, or 32-B5, respectively; Experimental Procedures
lanes 4, 6, and 8, ANG plus mAb (26-2F, 36u, and 32-B5, respectively)
and ANGBP; lane 9, molecular weight standards. The extent of the ANG Production and Preparation of mAb 26-2F
reduction in crosslinking of ANG to ANGBP due to preincubation and Its Fab Fragment
with mAB 26-2F (lane 4 versus lane 2) in this experiment, as deter- 	Glu-1 human ANG was produced with a recombinant system in
mined by densitometry, is 70%. Escherichia coli (Shapiro et al., 1988) and dissolved in water to a
concentration of 20 mg/ml. mAb 26-2F was obtained from ascites
fluid as described previously (Fett et al., 1994) and was dialyzed
extensively against 20 mM sodium phosphate (pH 7.0) and 10 mMon the intensity of the 58 kDa band (lanes 6 and 8), even
EDTA. Fab fragments were prepared by papain digestion with anwhen used in 300-fold molar excess (data not shown).
ImmunoPure Fab Preparation Kit (Pierce, Rockford, IL). Purity wasThe affinities of 36u and 32-B5 for the ANG variants ARH-
confirmed by SDS-PAGE, and the final products were dialyzed
II, W89M, and K40Q are indistinguishable from those of against a 1:150 dilution of phosphate-buffered saline (pH 7.2) and
ANG (K.A.O. and J.W.F., unpublished data), demonstra- concentrated to 20 mg/ml with a Centricon Plus-20 ultrafiltration
ting that the epitopes of these mAbs are distinct from device (Millipore, Bedford, MA).
that of 26-2F. The effect of mAb 26-2F on crosslinking
Crystallization and Data Collection for the Fab-ANG Complexof ANG to ANGBP strongly suggests that binding of the
The Fab-ANG complex was formed by mixing Fab and ANG in aantibody alters the conformation of the ANGBP binding
1:1.2 molar ratio and incubating overnight at 4C. Crystals weresite. However, it remains to be determined whether or
grown at 16C by the hanging drop vapor diffusion technique with
not this structural change corresponds to that seen in 30% PEG 8000 and 0.2 M Li2SO4 (pH 6.0–7.5) as the reservoir solu-
the crystal structure of the ANG-Fab 26-2F complex. tion. A full data set to 2.0 A˚ resolution was collected on station PX
9.6 of the SRS, Daresbury (UK), at 100 K from one crystal (with 20%
[v/v] glycerol in the reservoir buffer). This data set, merged with aBiological Implications
3.5 A˚ low-resolution data set collected with the same crystal, hadMonoclonal antibody 26-2F has been used successfully
an Rsym value of 6.1% and 98.9% overall completeness. The detailsin preclinical mouse models to inhibit the establishment
of data processing statistics are shown in Table 1. The programs
and/or metastatic dissemination of human colon, lung, DENZO and SCALEPACK were used for data integration and scaling
fibroblast, breast, and prostate tumors (Olson et al., (Otwinowski and Minor, 1997).
1994, 1995, 2002; Piccoli et al., 1998). The determination
of the 3D structure of the ANG-Fab complex now pro- Structure Determination
The structure was solved by molecular replacement with AmoRevides the information required to rationally construct
(Navaza, 1994). Different models for the V and the C regions froma maximally humanized version of 26-2F for potential
the Protein Data Bank were used in the search. Consistent peaksclinical use against cancer. Specifically, the structure
were found for most of the V domain models at (x, y, z)  (0.33,suggests that it may be sufficient to graft only four of
0.00, 0.19). The best model selected from the rotation function was
the six CDRs (L1, L3, H2, and H3) from the mouse anti- humanized anti-p185HER2 antibody 4D5 (Protein Data Bank code
body onto the human framework, since CDR-L2 forms 1FVC; Eigenbrot et al., 1993) (correlation coefficient of 18.3 for the
first peak and 9.9 for the second). Models for the C domain gave ano contacts and CDR-H1 makes only one interaction.
consistent peak in the translation function at (0.06, 0.00, 0.25), andThe structure also identifies five framework residues
the best models in the rotation functions were the C domains of thefrom the mouse protein that may be required to enhance
Fab fragments of mAbs HyHel-5 (Protein Data Bank code 3HFL;the avidity of a humanized IgG1 Fab; H47 (Trp) and
Cohen et al., 1996) (first peak 1.44  higher than the second peak)
H71 (Arg) interact with CDR-H2 residues that participate and TE33 (Protein Data Bank code 1TET; Shoham, 1993) (first peak
in the interface, and L49 (Tyr), H94 (Arg), and H103 (Trp) 1.63  higher than the second peak). At this stage, the 1TET C
domain was fixed, and the rotation peaks from the 1FVC modelall appear to help stabilize the conformation of CDR-
were used in order to find the position of the V domain. This searchH3. A humanized Fab of the type just described would
resulted in a correlation coefficient of 45.1% and an R factor ofcontain less than 13% murine-derived sequence and
48.0%. No symmetry-related clashes were observed, and the V andwould therefore be minimally immunogenic in patients.
C domains were found as expected for an antibody molecule. In
The 3D structure of the ANG-Fab complex may also the next step, the V and C domains were fixed, and a translation
aid in the design of peptide mimetic, small-molecule search was performed to locate the position of the ANG molecule.
The correlation coefficient at this stage went up to 51.8% and theinhibitors based on the critical CDR residues that con-
Angiogenin-Fab 26-2F Complex Structure
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R factor dropped further to 45.8% for the three components. Exami- mations for the canonical structures of immunoglobulins. J. Mol.
Biol. 273, 927–948.nation of the ANG position with the program O (Jones et al., 1991)
showed that it was indeed located in a suitable position to contact Berezov, A., Zhang, H.T., Greene, M.I., and Murali, R. (2001). Dis-
the CDRs of the Fab. abling erbB receptors with rationally designed exocyclic mimetics
of antibodies: structure-function analysis. J. Med. Chem. 44, 2565–
2574.Structure Refinement
Structure refinement was carried out with the molecular replacement Braden, B.C., Souchon, H., Eisele, J.L., Bentley, G.A., Bhat, T.N.,
model with CNS 1.0 (Bru¨nger et al., 1998) by gradual extension to Navaza, J., and Poljak, R.J. (1994). Three-dimensional structures
2.0 A˚, with molecular dynamics at 2000 K followed by Powell energy of the free and the antigen-complexed Fab from monoclonal anti-
minimization. Map calculations were performed with CNS with all lysozyme antibody D44.1. J. Mol. Biol. 243, 767–781.
reflections in the resolution range 40.0–2.0 A˚. Significant changes
Bru¨nger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P.,
in the structure were observed during the refinement. Most notably,
Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M.,
there was a large movement of the ANG region containing residues
Pannu, N.S., et al. (1998). Crystallography and NMR system: a new
60–69, with the altered conformation extending into the solvent.
software suite for macromolecular structure determination. Acta
Additionally, it was necessary to model residues 195–199 in CL, Crystallogr. D Biol. Crystallogr. 54, 905–921.
71–76 and 100–102 in VH, and 187–191 in CH in a different conforma-
Carter, P. (2001). Improving the efficacy of antibody-based cancertion, and an extended loop region in CH from 128 to 133 had to be
therapies. Nat. Rev. Cancer 1, 118–129.modeled de novo. Finally, five residues of the hinge region that joins
the Fab and Fc portions of the antibody were modeled with the aid CCP4 (Collaborative Computational Project 4). (1994). The CCP4
of the Fo  Fc electron density map (Harris et al., 1998). Water suite: programs for protein crystallography. Acta Crystallogr. D Biol.
molecules were incorporated into the structure if they had peak Crystallogr. 50, 760–763.
heights 3  in the Fo  Fc difference electron density maps and Chothia, C., and Lesk, A.M. (1987). Canonical structures for the
were within hydrogen bonding distance of appropriate atoms. Six hypervariable regions of immunoglobulins. J. Mol. Biol. 196,
molecules of glycerol from the cryoprotectant and eight sulfate ions 901–917.
were also identified in the structure and were included in the final
Chothia, C., Lesk, A.M., Tramontano, A., Levitt, M., Smith-Gill, S.J.,stages of refinement. Model refinement statistics and stereochemi-
Air, G., Sheriff, S., Padlan, E.A., Davies, D., Tulip, W.R., et al. (1989).cal parameters are given in Table 1.
Conformations of immunoglobulin hypervariable regions. Nature
342, 877–883.
Effect of mAbs on Crosslinking of ANG to ANG
Choy, E.H., Kingsley, G.H., and Panayi, G.S. (1993). Treatment withBinding Protein
anti-CD4 monoclonal antibody and acute interstitial nephritis. Arthri-Crosslinking was carried out essentially as described previously (Hu
tis Rheum. 36, 723–724.et al., 1991). 125I-ANG, 0.1 g, was incubated for 10 min at room
Choy, E.H.S., Schantz, A., Woody, J., Kingsley, G.H., and Panayi,temperature in the presence or absence of 10 g of mAb (26-2F,
G.S. (1994). Human anti-chimeric antibody response in rheumatoid36u, or 32-B5) in 40 l of PBS. An endothelial cell surface extract
arthritis patients treated with a chimeric anti-CD4 monoclonal anti-containing ANGBP (Hu et al., 1991) or PBS, 10 l, was then added,
body. Arthritis Rheum. 37, S340.and the mixtures were incubated for another 10 min, and then
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide crosslinker was Cohen, G.H., Sheriff, S., and Davies, D.R. (1996). Refined structure
added to a final concentration of 10 mM. After 30 min at room of the monoclonal antibody HyHel-5 with its antigen hen egg white
temperature, the reaction was quenched by the addition of Tris-HCl lysozyme. Acta Crystallogr. D Biol. Crystallogr. 52, 315–326.
to 100 mM. Samples were then subjected to SDS-PAGE separation Davies, D.R., and Cohen, G.H. (1996). Interactions of protein anti-
(10% acrylamide), and radiolabeled bands were visualized by auto- gens with antibodies. Proc. Natl. Acad. Sci. USA 93, 7–12.
radiography. Band intensities were quantified by densitometry (Hu
Eberle, K., Oberpichler, A., Trantakis, C., Krupp, W., Knupfer, M.,et al., 1991).
Tschesche, H., and Seifert, V. (2000). The expression of angiogenin
in tissue samples of different brain tumors and cultured glioma cells.
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